DR. DOUGLAS R GALASKO, MD
Neurology in La Jolla, CA
License number
California A45023
Category
Neurology
Type
Neurology
Address
Address
2
9350 Campus Point Dr Perlman Ambulatory Care Center - Neurology, La Jolla, CA 92037
232410 Neurology, San Diego, CA 92193
232410 Neurology, San Diego, CA 92193
Phone
(858) 657-8540
(858) 657-8557 (Fax)
(858) 249-6749
(858) 657-8557 (Fax)
(858) 249-6749
Professional information
Abeta 42 Lowering Agents
US Patent:
2002012, Sep 12, 2002
Filed:
Dec 7, 2001
Appl. No.:
10/012606
Inventors:
Edward Koo - La Jolla CA, US
Todd Golde - Ponte Vedra Beach FL, US
Douglas Galasko - San Diego CA, US
Todd Golde - Ponte Vedra Beach FL, US
Douglas Galasko - San Diego CA, US
International Classification:
A61K031/195, A61K031/192
US Classification:
514/569000, 514/570000, 514/567000
Abstract:
The invention provides a method of preventing, delaying, or reversing the progression of Alzheimer's disease by administering an Alowering agent to a mammal under conditions in which levels of Aare selectively reduced, levels of A8 are increased, and levels of Aare unchanged. The invention provides methods and materials for developing and identifying Alowering agents. In addition, the invention provides methods for identifying agents that increase the risk of developing, or hasten progression of, Alzheimer's disease. The invention also provides compositions of Alowering agents and antioxidants, Alowering agents and non-selective secretase inhibitors, as well as Alowering agents and acetylcholinesterase inhibitors. The invention also provides kits containing Alowering agents, antioxidants, non-selective secretase inhibitors, and/or acetylcholinesterase inhibitors as well as instructions related to dose regimens for Alowering agents, antioxidants, non-selective secretase inhibitors, and acetylcholinesterase inhibitors.
Abeta42 Lowering Agents
US Patent:
2005018, Aug 25, 2005
Filed:
Apr 25, 2005
Appl. No.:
11/113789
Inventors:
Edward Koo - La Jolla CA, US
Todd Golde - Ponte Vedra Beach FL, US
Douglas Galasko - San Diego CA, US
Sacha Weggen - Mainz, DE
Todd Golde - Ponte Vedra Beach FL, US
Douglas Galasko - San Diego CA, US
Sacha Weggen - Mainz, DE
Assignee:
Mayo Foundation for Medical Education and Research - Rochester MN
The Regents of The University of California - Oakland CA
The Regents of The University of California - Oakland CA
International Classification:
C12Q001/68, C12Q001/00
US Classification:
435004000, 435006000, 436086000
Abstract:
The invention provides a method of preventing, delaying, or reversing the progression of Alzheimer's disease by administering an Aβlowering agent to a mammal under conditions in which levels of Aβare selectively reduced, levels of Aβare increased, and levels of Aβare unchanged. The invention provides methods and materials for developing and identifying Aβlowering agents. In addition, the invention provides methods for identifying agents that increase the risk of developing, or hasten progression of, Alzheimer's disease. The invention also provides compositions of Aβlowering agents and antioxidants, Aβlowering agents and non-selective secretase inhibitors, as well as Aβlowering agents and acetylcholinesterase inhibitors. The invention also provides kits containing Aβlowering agents, antioxidants, non-selective secretase inhibitors, and/or acetylcholinesterase inhibitors as well as instructions related to dose regimens for Aβlowering agents, antioxidants, non-selective secretase inhibitors, and acetylcholinesterase inhibitors.
Douglas R Galasko, La Jolla CA
Specialties:
Neurologist
Address:
9350 Campus Point Dr, La Jolla, CA 92037
3350 La Jolla Village Dr, San Diego, CA 92161
3350 La Jolla Village Dr, San Diego, CA 92161
Board certifications:
American Board of Psychiatry and Neurology Certification in Neurology (Psychiatry and Neurology)
Dr. Douglas R Galasko, La Jolla CA - MD (Doctor of Medicine)
Specialties:
Neurology, Neuropsychiatry (Neurology)
Address:
UCSD Shiley Marcos Alzheimer
8950 Villa La Jolla Dr STE 129, La Jolla 92037
(858) 622-5800 (Phone)
UCSD Neurology Clinic
9350 Campus Point Dr STE B, La Jolla 92037
(858) 657-8540 (Phone)
8950 Villa La Jolla Dr STE 129, La Jolla 92037
(858) 622-5800 (Phone)
UCSD Neurology Clinic
9350 Campus Point Dr STE B, La Jolla 92037
(858) 657-8540 (Phone)
Certifications:
Neurology, 1989
Awards:
Healthgrades Honor Roll
Languages:
English
Education:
Medical School
University Of The Witwatersrand, Faculty Of Health Sciences
Graduated: 1979
Boston University Med Ctr/Univ Hp
Johns Hopkins Hospital
University Of The Witwatersrand, Faculty Of Health Sciences
Graduated: 1979
Boston University Med Ctr/Univ Hp
Johns Hopkins Hospital
Douglas Roger Galasko, La Jolla CA
Specialties:
Neurology, Geriatric Medicine, Geriatric Medicine
Work:
Ucsd Medical Group
9350 Campus Point Dr, La Jolla, CA 92037
9350 Campus Point Dr, La Jolla, CA 92037
Education:
University Of The Witwatersrand (1979)
Method Of Reducing Abeta42 And Treating Diseases
US Patent:
2008002, Jan 24, 2008
Filed:
Jun 21, 2007
Appl. No.:
11/766589
Inventors:
Edward Koo - La Jolla CA, US
Todd Golde - Ponte Vedra Beach FL, US
Douglas Galasko - San Diego CA, US
Sascha Weggen - Duesseldo, DE
Todd Golde - Ponte Vedra Beach FL, US
Douglas Galasko - San Diego CA, US
Sascha Weggen - Duesseldo, DE
Assignee:
Mayo Foundation for Medical Education and Research - Rochester MN
The Regents of The University of California - Oakland CA
The Regents of The University of California - Oakland CA
International Classification:
A61K 31/192, A61K 31/196, A61K 31/403, A61P 25/28
US Classification:
514411000, 514420000, 514567000, 514569000, 514570000, 514789000
Abstract:
The invention provides a method of preventing, delaying, or reversing the progression of Alzheimer's disease by administering an Aβlowering agent to a mammal under conditions in which levels of Aβare selectively reduced, levels of Aβare increased, and levels of Aβare unchanged. The invention provides methods and materials for developing and identifying Aβlowering agents. In addition, the invention provides methods for identifying agents that increase the risk of developing, or hasten progression of, Alzheimer's disease. The invention also provides compositions of Aβlowering agents and antioxidants, Aβlowering agents and non-selective secretase inhibitors, as well as Aβlowering agents and acetylcholinesterase inhibitors. The invention also provides kits containing Aβlowering agents, antioxidants, non-selective secretase inhibitors, and/or acetylcholinesterase inhibitors as well as instructions related to dose regimens for Aβlowering agents, antioxidants, non-selective secretase inhibitors, and acetylcholinesterase inhibitors.
Method Of Reducing Abeta42 And Treating Diseases
US Patent:
2006000, Jan 5, 2006
Filed:
Jun 28, 2005
Appl. No.:
11/170776
Inventors:
Edward Mang Koo - La Jolla CA, US
Todd Golde - Ponte Vedra Beach FL, US
Douglas Galasko - San Diego CA, US
Sascha Weggen - Mainz, DE
Todd Golde - Ponte Vedra Beach FL, US
Douglas Galasko - San Diego CA, US
Sascha Weggen - Mainz, DE
Assignee:
Mayo Foundation for Medical Education and Research - Rochester MN
The Regents of The University of California - Oakland CA
The Regents of The University of California - Oakland CA
International Classification:
A61K 31/405, A61K 31/192, G01N 33/573
US Classification:
514420000, 514570000, 514569000
Abstract:
The invention provides a method of preventing, delaying, or reversing the progression of Alzheimer's disease by administering an Aβlowering agent to a mammal under conditions in which levels of Aβare selectively reduced, levels of Aβare increased, and levels of Aβare unchanged. The invention provides methods and materials for developing and identifying Aβlowering agents. In addition, the invention provides methods for identifying agents that increase the risk of developing, or hasten progression of, Alzheimer's disease. The invention also provides compositions of Aβlowering agents and antioxidants, Aβlowering agents and non-selective secretase inhibitors, as well as Aβlowering agents and acetylcholinesterase inhibitors. The invention also provides kits containing Aβlowering agents, antioxidants, non-selective secretase inhibitors, and/or acetylcholinesterase inhibitors as well as instructions related to dose regimens for Aβlowering agents, antioxidants, non-selective secretase inhibitors, and acetylcholinesterase inhibitors.